Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Lisa Licitra et al.|The Lancet|2018Cited by 1.7k
A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma: epidemiology and prognostic factorsSarah Atallah, B. Baujat, Odile Casiraghi et al.|European Journal of Cancer|2020Cited by 86